T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

A new study reveals that even low-dose, chronic exposure to air pollution can trigger liver inflammation, fibrosis, and metabolic disruptions, increasing the risk of fatty liver disease and other ...

Researchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

The lack of NHS funded testing for this type of cancer in Scotland means patients are denied targeted treatments unless they ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

The year 2024 was momentous for metabolic dysfunction-associated steatotic ... 60 weeks to investigate the progression from MASLD to hepatocellular carcinoma.

Mr Carey, a sustainable tourism consultant, is heading to the House of Commons on February 26 and to the Scottish Parliament on June 11 in support of UK cholangiocarcinoma charity AMMF’s Rethink Liver ...